|Mr. Franc Del Fosse||Gen. Counsel and Corp. Sec.||307.9k||N/A||45|
|Mr. Saeed Motahari||Pres, CEO & Director||N/A||N/A||51|
|Mr. Andrew G. Long||Chief Financial Officer||N/A||N/A||N/A|
|Mr. Brian Jennings||VP of Sales||N/A||N/A||N/A|
|Mr. Ariyapadi N. Krishnaraj||VP of Marketing and Managed Care||N/A||N/A||N/A|
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. Its lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.
INSYS Therapeutics, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 10. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 10; Compensation: 9.